C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

Patents for C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637)
10/2002
10/17/2002	WO2002040665A3 Complementing cell lines
10/17/2002	WO2001060847A9 Avirulent, immunogenic flavivirus chimeras
10/17/2002	US20020151686 Polypeptide for use in the treatment and prevention of infections
10/17/2002	US20020151509 Adeno-associated viral vector-mediated delivery of DNA to cells of the liver
10/17/2002	US20020151069 Expression vector for use as gene transfer tool in genetic engineering
10/17/2002	US20020151067 Nucleotide sequences coding polypeptide for use in the treatment of viral diseases
10/17/2002	US20020151033 Viral vector for use as tool in genetic engineering
10/17/2002	US20020151032 Generation of preferential viral vector; obtain cell, incubate with viral nucleotide sequences, propagate, recover nucleotide sequences
10/17/2002	US20020150881 Recovering nucleotide sequences coding preferential protein; obtain phage coding preferential protein, express protein, separate phage displaying binding domain, recover phage displaying chimeric binding protein on surface
10/17/2002	US20020150562 Viral preparations, vectors, immunogens, and vaccines
10/17/2002	US20020148281 Single riser/single capillary blood viscometer using mass detection or colum height detection
10/17/2002	CA2443039A1 Artificial chromosomes comprising ehv sequences
10/17/2002	CA2442092A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	CA2441626A1 Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
10/16/2002	EP1248648A2 Vaccination against canine herpesvirus infection and vaccines
10/16/2002	EP0750669B1 MODIFIED PAPILLOMA VIRUS L2 PROTEIN AND VLPs FORMED THEREFROM
10/15/2002	US6465634 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
10/15/2002	US6465254 Nucleotide sequence (loxp site) where in the presence of recombinase cre, recombination with a wild-type loxp site can not occur, and recombination between two mutant loxp sites having the identical sequence occur; gene transfer
10/15/2002	US6465253 Vectors and methods for gene transfer to cells
10/15/2002	US6465168 Contacting blood with critical or supercritical fluid
10/15/2002	CA2263725C Immortalized cell lines for virus growth
10/10/2002	WO2002079464A2 Viral vectors
10/10/2002	WO2002079239A2 Chimeric filovirus glycoprotein
10/10/2002	WO2002078734A1 Production of peptides in plants as n-terminal viral coat protein fusions
10/10/2002	WO2002078631A2 Improved conditionally replicating vectors for inhibiting viral infections
10/10/2002	WO2002078621A2 Replication-competent recombinant virus and methods of use thereof
10/10/2002	WO2002078437A2 Novel pesticidal toxins
10/10/2002	WO2002004007A9 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
10/10/2002	WO2002000694A3 Modified morbillivirus v proteins
10/10/2002	WO2001090340A3 Assembly of large viral genomes and chromosomes from subclones
10/10/2002	US20020147996 Diagnosing and treating cancer cells using Sal2
10/10/2002	US20020147172 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
10/10/2002	US20020147169 In vivo selection method for determining inhibitory RNA molecules
10/10/2002	US20020146710 Detecting preferental polypeptide in sample; obtain cells, transform with vector, recover transformed cells, monitor and evaluate gene expression in transformed cells
10/10/2002	US20020146683 Modified hiv env polypeptides
10/10/2002	US20020146433 Vaccines
10/10/2002	US20020146432 Porcine circoviruses, vaccines and diagnostic reagents
10/10/2002	US20020146431 For prophylaxis of porcine multisystemic wasting syndrome (PMWS)
10/10/2002	DE10116594A1 Künstliche Chromosomen, die EHV-Sequenzen umfassen Include artificial chromosomes EHV sequences
10/10/2002	CA2442594A1 Vip3 pesticidal toxin from bacillus thuringiensis
10/10/2002	CA2442149A1 Viral vectors
10/10/2002	CA2441084A1 Improved conditionally replicating vectors for inhibiting viral infections
10/09/2002	EP1246920A2 Prevention of affections associated with porcine circovirus-2
10/09/2002	EP1246904A2 Method using filtration aids for the separation of virus vectors from nucleic acids and other cellular contaminants
10/09/2002	EP1246902A2 Cell line for preparing and producing ovine adenovirus vectors
10/09/2002	EP0900087B1 Process for disintegrating nucleic acids and preparing biological products of guaranteed quality
10/09/2002	CN1373807A Mosaic infections bursal disease virus vaccines
10/08/2002	US6461608 E. coli
10/06/2002	CA2377725A1 Conditionally replicative and conditionally active viruses
10/03/2002	WO2002077246A2 Site-targeted transformation using amplification vectors
10/03/2002	WO2002077211A2 A virus (cryptovirus) within the rubulavirus genus and uses therefor
10/03/2002	WO2002077210A2 Methods to culture circovirus
10/03/2002	WO2002077206A1 Compositiona and methods useful for hcv infection
10/03/2002	WO2002076216A1 Viral vectors and their use in therapeutic methods
10/03/2002	WO2002056828A3 Helper virus-free herpes virus amplicon particles and uses thereof
10/03/2002	WO2002018595A3 Moraxella polypeptides and corresponding dna fragments and uses thereof
10/03/2002	US20020144302 Expression vector coding protein for use in the treatment of liver disorders
10/03/2002	US20020142986 Used in the diagnosis or prognosis of liver associated disorders
10/03/2002	US20020142455 Enhanced replication of HCV RNA
10/03/2002	US20020142449 Compositions and methods useful for HCV infection
10/03/2002	US20020142429 Elongation factor-2 kinase (EF-2 kinase) and methods of use therefor
10/03/2002	US20020142350 Viral nucleotide sequences for use in the prevention and treatment of viral diseases
10/03/2002	US20020141978 Retroviral vectors
10/03/2002	US20020141975 Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
10/03/2002	CA2442254A1 Site-targeted transformation using amplification vectors
10/03/2002	CA2441688A1 Compositions and methods useful for hcv infection
10/03/2002	CA2441663A1 Viral vectors and their use in therapeutic methods
10/03/2002	CA2436208A1 A novel virus (cryptovirus) within the rubulavirus genus and uses therefor
10/02/2002	EP1245678A2 Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
10/02/2002	EP1244805A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes
10/02/2002	EP1244798A2 Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
10/02/2002	EP1244790A2 Nucleic acids encoding polypeptides having chips activity
10/02/2002	EP1244773A1 Mutated hepatitis b virus, its nucleic and protein constituents and uses thereof
10/02/2002	EP1244469A2 Mutant simplex virus for treating unwanted hyperproliferative cell growth
10/02/2002	CN1371992A Method for removing organic solvent used as virus inactivator and/or detergent
10/01/2002	US6459393 Apparatus and method for optimized self-synchronizing serializer/deserializer/framer
10/01/2002	US6458587 Transfecting cells with a recombinant adeno-associated virus (aav) which can be package into infectious aav virions, a helper aav vector essential for replication and packaging and a productive vector which cannot be packaged into the virion
10/01/2002	US6458586 Replication of defective vectors with mutations and deletions; gene therapy, vaccines, genetic engineering
10/01/2002	US6458578 Recombinant cell line produces adenoviral gene products E1 and DEF-A, and/or DEF-B
10/01/2002	US6458577 Methods of culturing and assaying a virus in a specimen and compositions and cell lines for doing the same
10/01/2002	US6458567 Hepatitis C Virus ribozymes
10/01/2002	US6458560 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
10/01/2002	US6458529 Assays for promoter operability in central nervous system cells
10/01/2002	US6458527 Using synthetic or recombinant polypeptides as gag antigen; diagnosis of human immunodeficiency virus
09/2002
09/26/2002	WO2002074963A1 Dengue viruses that are replication defective in mosquitos for use as vaccines
09/26/2002	WO2002074941A1 Reporter virus comprising heterologous envelope proteins
09/26/2002	WO2002074940A1 Method of extracting virus from cell culture
09/26/2002	WO2002074335A2 Equine herpesvirus vaccine
09/26/2002	WO2002074243A2 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
09/26/2002	WO2002046214A3 Immunomodulatory protein derived from the yaba monkey tumor virus
09/26/2002	WO2002042767A3 Step-wise process to recover or eliminate biological substances by flotation from underlayered colloidal medium
09/26/2002	WO2002000693A3 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
09/26/2002	WO2000034495A3 A method of genetically modifying very primitive quiescent human hematopoietic stem cells
09/26/2002	US20020138207 Flexible processing apparatus for isolating and purifying viruses, soluble proteins and peptides from plant sources
09/26/2002	US20020137889 Stress resistant retroviruses
09/26/2002	US20020137186 Lymphotropic agents and vectors
09/26/2002	US20020136740 With an antigen that has an epitope of hepatitis c virus
09/26/2002	US20020136739 Subunit respiratory syncytial virus preparation
09/26/2002	US20020136710 Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
09/25/2002	EP1243656A2 Novel baculovirus transfer vectors and recombinant baculoviruses for exogenous gene expression

1 ... 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 ... 267